Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Subscribe To Our Newsletter & Stay Updated